A blockbuster breast cancer niche has Roche and Sanofi in the lead

A blockbuster breast cancer niche has Roche and Sanofi in the lead

Submitted by admin on February 19, 2020 - 11:33pm
Source: 
EP Vantage
News Tags: 
Sanofi
Roche
SAR439859
RG6171
clinical trials
Serds
breast cancer
Headline: 
A blockbuster breast cancer niche has Roche and Sanofi in the lead
snippet: 

As SAR439859 and RG6171 move into pivotal testing, the Serd approach to treating one form of breast cancer generates renewed interest.

Do Not Allow Advertisers to Use My Personal information